Epic Bio to Participate in the BMO Virtual Spotlight Series

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022. Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D.,...

Click to view original post